A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Status:
Not yet recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

The reason for this study is to see if the CD73 inhibitor HLX23 alone is safe and effective in participants with advanced solid cancer.

Phase 1

Shanghai Henlius Biotech